These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35059774)

  • 1. Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kodama Y; Kato Y
    Osteoporos Int; 2022 Jun; 33(6):1265-1273. PubMed ID: 35059774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
    Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
    J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
    Cosman F; Kendler DL; Langdahl BL; Leder BZ; Lewiecki EM; Miyauchi A; Rojeski M; McDermott M; Oates MK; Milmont CE; Libanati C; Ferrari S
    Osteoporos Int; 2022 Jun; 33(6):1243-1256. PubMed ID: 35165774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
    Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy for osteoporosis in older adults.
    Reid IR; Billington EO
    Lancet; 2022 Mar; 399(10329):1080-1092. PubMed ID: 35279261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
    Poole KE; Treece GM; Pearson RA; Gee AH; Bolognese MA; Brown JP; Goemaere S; Grauer A; Hanley DA; Mautalen C; Recknor C; Yang YC; Rojeski M; Libanati C; Whitmarsh T
    J Bone Miner Res; 2022 Feb; 37(2):256-264. PubMed ID: 34738660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
    Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
    Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
    Hong N; Shin S; Lee S; Rhee Y
    Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.